NFKB1 and Alzheimer disease: Since AD is a multifactorial disease, combined therapies with different mechanisms of action (for instance, an inhibitor of RAGE/NF-κB pathway together with a ROS scavenger) may enhance the therapeutic effects of astrocytes in early stages of AD.